Repositioning Candidate Details
| Candidate ID: | R0989 |
| Source ID: | DB06347 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Cenisertib |
| Synonyms: | Cenisertib |
| Molecular Formula: | C24H30FN7O |
| SMILES: | [H][C@@]12C[C@@]([H])(C=C1)[C@@H]([C@@H]2NC1=C(F)C=NC(NC2=CC=C(N3CCN(C)CC3)C(C)=C2)=N1)C(N)=O |
| Structure: |
|
| DrugBank Description: | Cenisertib is an aurora kinase inhibitor. |
| CAS Number: | 871357-89-0 |
| Molecular Weight: | 451.55 |
| DrugBank Indication: | Investigated for use/treatment in solid tumors, leukemia (myeloid), myelodysplastic syndrome, and cancer/tumors (unspecified). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | R763 is a highly potent and specific inhibitor of Aurora kinase, which has been shown to block proliferation and trigger apoptosis (cell death) in several tumor cell lines including cervical, colon, lung, pancreas and prostate. The over-expression of Aurora kinase can cause cells to rapidly develop an abnormal number of chromosomes. Elevated levels of Aurora kinase are frequently associated with various human cancers and inhibition of this enzyme disrupts cell division and promotes apoptosis. A probable target for R763 is Aurora kinase A (serine/threonine protein kinase 6). |
| Targets: | Aurora kinase A |
| Inclusion Criteria: | Therapeutic strategy associated |
